How much revenue does Hansoh Pharmaceutical Group make?

Hansoh Pharmaceutical Group reported 15.03 billion CNY in revenue for fiscal year 2025, up 22.6% from 12.26 billion HKD in fiscal year 2024.

What companies are similar to Hansoh Pharmaceutical Group?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Innovent BIO (1801.HK), Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK), Akeso, Inc. (9926.HK), Shanghai Henlius Biotech, Inc. (2696.HK).

Hansoh Pharmaceutical Group Company Limited (3692.HK) Stock

About Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products i...

At a glance

Hansoh Pharmaceutical Group reported revenue of 15.03 billion CNY for fiscal year 2025, up 22.6% from fiscal year 2024, and net income of 5.56 billion CNY.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.